WebDoctor Encyclopedia

Article

Androgen Deprivation Therapy (ADT)

What is androgen deprivation therapy?

Androgen deprivation therapy (ADT) is a type of hormone therapy for prostate cancer. It lowers the level of testosterone and other male hormones (androgens) in the body, or stops them from acting on cancer cells. Most prostate cancers rely on androgens to grow, so taking them away can shrink the cancer or slow it down for months to years.

ADT is sometimes called hormone treatment, androgen suppression or medical castration. It is usually given as injections or implants every one to six months, or as daily tablets. In the past, it was often given by an operation to remove the testicles, which make most of the body’s testosterone.

ADT is one of the oldest and most effective treatments for prostate cancer. Its discovery in the 1940s, by the surgeon Charles Huggins, earned a Nobel Prize. Today, it is used both to help cure prostate cancer when combined with radiotherapy, and to control cancer that has spread.

1. Key facts at a glance

Feature Details
Type of treatment Hormone therapy
Main use Prostate cancer, especially higher-risk, recurrent or advanced disease
How it is given Injections or implants every 1, 3 or 6 months; some daily tablets
Course length From 4-6 months to 3 years with radiotherapy; often long term for advanced cancer
Often combined with Radiotherapy, newer hormone tablets or chemotherapy
Common side effects Hot flushes, loss of sex drive, erection problems, tiredness, weight gain
Long-term risks Bone thinning, muscle loss, diabetes, heart and blood vessel problems

2. How it works

Where androgens come from

Source Share of androgens How ADT acts
Testicles Around 90-95% Stopped by LHRH agonists, antagonists or surgery
Adrenal glands A small amount Targeted by drugs such as abiraterone
Cancer cells themselves Small amounts, increasing in advanced disease Targeted by newer hormone drugs

Types of ADT

Type Examples How it works
LHRH (GnRH) agonists Goserelin, leuprorelin, triptorelin Overstimulate the pituitary gland until it stops signalling the testicles; testosterone briefly rises before it falls
LHRH (GnRH) antagonists Degarelix, relugolix Block the pituitary signal straight away; no initial rise
Anti-androgens Bicalutamide Block androgens from acting on cancer cells
Surgical castration Bilateral orchiectomy Removes the main source of testosterone permanently

The tumour flare

When an LHRH agonist is started, testosterone rises for one to two weeks before it falls. This can briefly worsen symptoms such as bone pain. To prevent it, an anti-androgen tablet is usually taken for a few weeks around the first injection. Antagonists do not cause a flare.

Newer hormone drugs

Drug How it works
Abiraterone Blocks androgen production in the adrenal glands and the tumour
Enzalutamide, apalutamide, darolutamide Stronger androgen receptor blockers

These drugs are given together with ADT, not instead of it.

3. Who it is for

Conditions treated

Condition Role of ADT
Prostate adenocarcinoma Combined with radiotherapy for intermediate and high-risk cancer; main treatment for recurrent and advanced cancer
Salivary duct carcinoma Used for advanced tumours that carry androgen receptors

Situations in prostate cancer

Situation Typical use
Intermediate-risk localised cancer with radiotherapy Short course, often about 4-6 months
High-risk localised cancer with radiotherapy Longer course, often 18 months to 3 years
Rising PSA after surgery or radiotherapy Depends on PSA speed and scan findings
Metastatic hormone-sensitive cancer Continuous ADT, usually combined with a newer hormone drug and sometimes chemotherapy
Castration-resistant cancer ADT is continued alongside further treatments

Radiotherapy may be delivered as external beam treatment, including proton beam therapy in some centres, or as brachytherapy.

When ADT is usually not needed

Men with low-risk prostate cancer under active surveillance, or after successful surgery with no signs of remaining cancer, do not usually need ADT. The side effects outweigh any benefit in these situations.

4. Before treatment

Step Why it is done
PSA and testosterone levels Baseline for later comparison
Bone density scan Checks for bone thinning, especially for long-term treatment
Blood sugar and cholesterol ADT can affect metabolism
Blood pressure and heart history ADT may affect heart health
Discussion of side effects Including effects on sex life and mood
Exercise plan Helps prevent muscle and bone loss

5. What to expect: step by step

Step What happens
1. Anti-androgen tablets If an LHRH agonist is used, tablets often start a week or two before the first injection
2. First injection or implant Given by a nurse or doctor under the skin of the abdomen or into a muscle
3. Follow-up visit Usually after about 3 months, with a PSA test
4. Repeat injections Every 1, 3 or 6 months, depending on the drug
5. Monitoring Regular PSA, testosterone and other blood tests
6. Combined treatment Radiotherapy usually starts after 2-3 months of ADT in localised cancer
7. Review Decision to stop at the planned time, or continue for advanced disease

Keep a note of your injection dates. Missing or delaying an injection can allow testosterone to rise again.

Intermittent ADT

In some men with rising PSA but no visible spread, ADT may be given in cycles: treatment is stopped once PSA falls very low and restarted when it rises again. This allows testosterone and quality of life to recover between cycles. It is not suitable for everyone.

What the PSA tells you

The PSA blood test is the main way to tell whether ADT is working. In most men, PSA falls steeply within the first few months. A very low PSA is a good sign. A steady rise while testosterone remains low suggests the cancer is becoming resistant, and your team will discuss next steps.

6. Side effects and risks

Side effect How common What helps
Hot flushes and sweats Very common Layered clothing; some medicines can help
Loss of sex drive Very common Talking with your partner and team
Erection problems Very common Tablets, injections or devices may help
Tiredness Common Regular exercise
Weight gain and muscle loss Common Resistance and aerobic exercise; healthy diet
Breast swelling or tenderness Common with anti-androgen tablets Preventive radiotherapy or tamoxifen in some men
Mood changes and low mood Common Support, counselling and exercise
Memory or concentration changes Some men Usually mild
Bone thinning (osteoporosis) Increases with time Exercise, calcium, vitamin D and bone-strengthening drugs
Diabetes Increased risk Regular blood sugar checks
Heart and blood vessel problems Possible increased risk Blood pressure, cholesterol and lifestyle management
Anaemia Mild, common Usually no treatment needed

Heart risk

A review of studies on heart effects found that observational studies consistently link ADT with heart disease, while randomised trials have not shown this as reliably. Among the drugs studied, abiraterone was linked with a higher risk of cardiac problems (Hu et al., 2020).

The role of exercise

A review of exercise for men on ADT found strong evidence that exercise helps prevent loss of muscle mass and strength, eases fatigue and supports physical function. Evidence for improvements in mood, bone health and sexual function was moderate (Edmunds et al., 2020).

7. Results and outlook

Study Main finding
EORTC trial, locally advanced prostate cancer (415 men) Adding 3 years of goserelin to radiotherapy improved five-year survival from 62% to 78% (Bolla et al., 2002)
Review of metastatic hormone-sensitive prostate cancer ADT alone is not enough for lasting control; adding a newer hormone drug and/or docetaxel improves survival in several large trials (Hussain et al., 2024)

Why ADT is combined with radiotherapy

Radiotherapy kills prostate cancer cells more effectively when they are deprived of androgens. Starting ADT a few months before radiotherapy also shrinks the prostate, which can make the treatment area smaller. The EORTC trial was one of the first to show that this combination helps men live longer.

How long does ADT work?

In advanced cancer, ADT usually controls the disease for a number of years, especially when combined with newer drugs. Over time, most cancers find ways to grow despite low testosterone. This stage is called castration-resistant prostate cancer, and other treatments are then added.

8. Recovery and aftercare

Living well on ADT

Area Tips
Exercise Aim for regular aerobic exercise and resistance training each week
Diet Balanced diet with enough calcium and vitamin D; limit sugar and processed foods
Smoking and alcohol Stop smoking and keep alcohol within recommended limits
Hot flushes Avoid triggers such as hot drinks, spicy foods and alcohol
Relationships Talk openly with your partner; ask for psychosexual support
Mood Tell your team if you feel low or anxious

Protecting your bones

Long-term ADT speeds up bone loss and increases the risk of fractures. Weight-bearing exercise, such as brisk walking and resistance training, helps keep bones strong. Your team may recommend calcium and vitamin D supplements. If a bone density scan shows thinning, medicines such as bisphosphonates or denosumab can reduce fracture risk.

Partners and relationships

ADT changes how men feel about sex and intimacy, and partners are often affected too. Many couples find new ways to stay close, with or without sex. Specialist nurses, psychosexual therapists and prostate cancer support groups can help couples talk through these changes.

After stopping ADT

When short-term ADT ends, testosterone usually recovers over 6-12 months, but this can take longer in older men or after long treatment. Some side effects, such as hot flushes and low sex drive, then gradually ease.

Follow-up

Check Typical timing
PSA Every 3-6 months
Testosterone When needed to confirm suppression
Bone density Every 1-2 years on long-term ADT
Blood sugar, cholesterol and blood pressure At least yearly

Feeling like yourself

Some men describe feeling less like themselves on ADT, with lower energy and motivation. These feelings are valid and common. Staying active, keeping up social contacts and hobbies, and talking openly with your team about how you feel can make a real difference.

9. Alternatives

Alternative When it is considered
Active surveillance Low-risk localised cancer
Radical prostatectomy Localised cancer in fit men
Radiotherapy without ADT Some lower-risk cancers
Bilateral orchiectomy Permanent alternative to injections; a different operation from radical orchiectomy for testicular cancer
Anti-androgen tablets alone Occasionally, to preserve sexual function, though usually less effective
Clinical trials New hormone and targeted treatments

Your team can help you weigh the benefits of ADT against its side effects at each stage of treatment.

10. Frequently asked questions

Question Answer
Is ADT chemotherapy? No; it is hormone therapy
Will I lose my hair? No; body hair may thin a little
Will my sex life change? Most men have reduced desire and erections; support is available
Can I stop the injections? Only after discussing it with your team
Does ADT cure prostate cancer? Alone, usually not; with radiotherapy it improves cure rates
Will I grow breasts? Some men get breast swelling, especially with anti-androgen tablets
Can I still work and exercise? Yes; exercise is strongly encouraged

11. Questions to ask your care team

  • Why do I need ADT, and for how long?
  • Which drug will I have, and how often?
  • Should I have a bone density scan?
  • What can I do to reduce side effects?
  • Will ADT affect my heart or diabetes risk?
  • What support is there for sexual changes?
  • Will I also need a newer hormone drug or chemotherapy?

Resources

  1. Bolla, M. et al. (2002) ‘Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial’, The Lancet, 360(9327), pp. 103-106.
  2. Edmunds, K. et al. (2020) ‘The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review’, Supportive Care in Cancer, 28(12), pp. 5661-5671.
  3. Hu, J.R. et al. (2020) ‘Cardiovascular effects of androgen deprivation therapy in prostate cancer: contemporary meta-analyses’, Arteriosclerosis, Thrombosis, and Vascular Biology, 40(3), pp. e55-e64.
  4. Hussain, M. et al. (2024) ‘Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review’, JAMA Oncology, 10(6), pp. 807-820.
  5. National Cancer Institute (2026) Hormone Therapy for Prostate Cancer. Available at: https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet (Accessed: October 2026).
  6. National Cancer Institute (2026) Prostate Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.